Summit Partners Public Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Summit Partners Public Asset Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100,000	Closed	-$19.9M	–	138
2025 Q3	$19.9M	Sell	100,000 -30,000	-23%	-$5.6M	0.41%	71
2025 Q2	$22.4M	Buy	+130,000	New	+$21.2M	0.57%	54
2024 Q4	–	Sell	-55,101	Closed	-$7.24M	–	154
2024 Q3	$8.23M	Sell	55,101 -178,572	-76%	-$24.1M	0.25%	82
2024 Q2	$31.9M	Buy	233,673 +8,562	+4%	+$1.16M	1.22%	31
2024 Q1	$34M	Buy	+225,111	New	+$32.1M	1.17%	29
2023 Q2	–	Sell	-169,693	Closed	-$18.2M	–	134
2023 Q1	$18.2M	Sell	169,693 -3,058	-2%	-$350K	0.75%	51
2022 Q4	$21.1M	Buy	+172,751	New	+$20.1M	1.33%	32
2022 Q2	–	Sell	-58,651	Closed	-$6.88M	–	142
2022 Q1	$6.88M	Buy	+58,651	New	+$6.79M	0.24%	86

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Summit Partners Public Asset Management's ASND Position: Q4 2025 in Review

Summit Partners Public Asset Management sold out of Ascendis Pharma A/S (ASND) in Q4 2025, closing a stake of 100,000 shares — an estimated $19.9M sold.

Summit Partners Public Asset Management first reported a position in ASND in Q1 2022 and held it in 8 quarters. The position peaked at $34M in Q1 2024. 302 funds tracked by Wall St. Rank hold ASND as of Q4 2025.

Summit Partners Public Asset Management reported no remaining Ascendis Pharma A/S position as of Q4 2025 after selling out during the quarter.
Summit Partners Public Asset Management sold 100,000 Ascendis Pharma A/S shares in Q4 2025, an estimated $19.9M.
Summit Partners Public Asset Management first reported a position in Ascendis Pharma A/S in Q1 2022 and held it in 8 quarters.
Summit Partners Public Asset Management's Ascendis Pharma A/S position peaked at $34M in Q1 2024.
302 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2025.

Based on Summit Partners Public Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.